Retatrutide weight loss rivals bariatric surgery

Beyond Ozempic: Eli Lilly’s Retatrutide Hits 30% Weight Loss | The End of Bariatric Surgery?Is the era of weight-loss surgery coming to an end? In today’s episode, we break down the explosive results of the Phase 3 TRIUMPH-1 trial for Eli Lilly’s next-generation drug, Retatrutide. We analyze how this "Triple G" injectable—which targets GLP-1, GIP, and glucagon receptors—helped patients lose an average of 28.3% of their body weight (over 70 lbs) in 80 weeks, with the heaviest participants reaching a staggering 30.3% loss.We dive into why experts are calling this a "game changer" that rivals gastric bypass surgery. We also explore the surprising data on the 4mg low dose, which offered high efficacy with a tolerability profile even better than the placebo. Plus, we discuss the side effects—from nausea to the rare nerve sensation known as dysesthesia—and what this means for the global $100 billion obesity market as Lilly races against Novo Nordisk. If you want to understand the future of metabolic health, this is the episode you can't miss.Become a supporter of this podcast: https://www.spreaker.com/podcast/scitech-brief--6846358/support.This episode includes AI-generated content.